EGFR and exocrine pancreatic carcinoma: We previously reported increased anti-tumor activity of ADCs ST8154AA4 and ST8155AA1 (cetuximab-HDACi) compared to cetuximab in EGFR+ tumor models including pancreatic carcinoma CAPAN-1 (11).